Eric Van Cutsem
Hebron University(PS)National Institutes of Health(US)Universitair Ziekenhuis Leuven(BE)University of Chicago(US)Boston Biomedical (United States)(US)Vall d'Hebron Hospital Universitari(ES)National Cancer Institute(US)Diagnostics for the Real World (United States)(US)Foundation Medicine (United States)University of Pennsylvania(US)KU Leuven(BE)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, Genetic factors in colorectal cancer
Most-Cited Works
- → Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial(2010)7,196 cited
- → Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine(2013)6,560 cited
- → Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer(2004)5,036 cited
- → Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer(2009)3,835 cited
- → ESMO consensus guidelines for the management of patients with metastatic colorectal cancer(2016)3,389 cited
- → Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer(2008)3,144 cited